Senior Pharmacovigilance Lead

Biogen reported second-quarter results exceeding Wall Street expectations, with revenue rising 3% year-over-year to $2.74 billion, above the $2.47 billion consensus estimate. Adjusted earnings reached $3.60 per share, beating forecasts of $2.89. The company's Growth Portfolio generated $1.06 billion in revenue, up 24% and surpassing its multiple sclerosis franchise for the first time. Alzheimer's treatment Leqembi recorded $184 million in global sales, whilst Skyclarys revenue jumped 29% to $168 million and Zurzuvae climbed 53% to $71 million. Biogen raised its 2026 underlying earnings guidance to $15.85–$16.85 per share, up from $15.25–$16.25 previously. The company expects full-year revenue to increase by a mid-single-digit percentage.

Biogen Q2 results lift shares despite MS weakness. Key moments. * Biogen's second-quarter adjusted earnings of $3.60 per share and revenue of $2.74 billion exceeded Wall Street expectations. * The company reduced its 2026 adjusted earnings outlook to a range of $12 to $13 per share, citing a $3.85-per-share impact from acquisition-related charges. * Leqembi global sales rose 15% year over year to about $184 million, while legacy multiple sclerosis drug sales declined 13% to $963 million. Quarterly Performance and outlook. On July 29, Biogen reported that its second-quarter profit and revenue surpassed analyst forecasts, supported by robust demand for its rare-disease therapies. This strength helped counter ongoing weakness in the company's older multiple sclerosis (MS) franchise. For the quarter ended June 30, Biogen posted adjusted earnings of $3.60 per share, topping the consensus expectation of $2.95 per share. Quarterly revenue reached $2.74 billion, ahead of the projected $2.46 billion. Despite the better-than-expected quarter, Biogen trimmed its 2026 adjusted earnings per share (EPS) target. The company now anticipates 2026 adjusted EPS between $12 and $13, down from its prior range of $14.25 to $15.25. The revised guidance incorporates a $3.85-per-share drag from acquisition-related charges. Analysts had been forecasting 2026 profit of $12.72 per share, based on data compiled by LSEG. Impact of strategic acquisitions. Biogen highlighted that its $5.6 billion acquisition of Apellis Pharmaceuticals earlier this year is expected to reduce annual profit by $0.85 per share. The Apellis transaction is Biogen's largest deal since its 2023 acquisition of Reata Pharmaceuticals. Through the Apellis purchase, Biogen gained an entry point into treatments for kidney disease and obtained two already-approved rare-disease medications. Those two drugs together generated approximately $689 million in revenue last year. | Metric / Item | Detail | | Apellis acquisition value | $5.6 billion | | Annual EPS impact of Apellis deal | $0.85 per share | | Total acquisition-related EPS impact in 2026 guidance | $3.85 per share | | Revenue from two acquired rare-disease drugs (last year) | About $689 million | Alzheimer's franchise and product pipeline. Investors are monitoring whether Biogen's recent transactions and newer therapies, including its Alzheimer's treatment Leqembi, can restore growth and help the company manage intensifying competition and pricing pressure on its aging MS brands. Global sales of Leqembi, which Biogen develops in partnership with Eisai, increased 15% from a year earlier to about $184 million. The company noted that demand strengthened after initial concerns about cost, efficacy, and side effects weighed on the product's early launch. Biogen stated that it expects recently granted U.S. approvals for a more convenient under-the-skin version of Leqembi to support further adoption among patients. Multiple sclerosis portfolio under pressure. While newer and rare-disease products contributed to growth, Biogen's legacy MS portfolio continued to face headwinds. Sales of older MS drugs, including Tecfidera, declined 13% year over year to $963 million. | Segment / Product | Latest Reported Performance | | Leqembi global sales | About $184 million, up 15% year over year | | Legacy MS drugs (including Tecfidera) | $963 million, down 13% year over year | | Total quarterly revenue | $2.74 billion (vs. estimate of $2.46 billion) | | Adjusted EPS for the quarter | $3.60 (vs. expectation of $2.95) | As Biogen works through competitive and pricing challenges in its established MS business, the company's recent acquisitions and emerging therapies, particularly in rare diseases and Alzheimer's, remain central to its strategy for future growth.

Biogen appoints Michael J. Parini as Chief Legal Officer. July 15, 2026 08:15 ET | Source: Biogen Inc. CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) - Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A. Viehbacher, President and Chief Executive Officer. In this role, Mr. Parini will have responsibility for oversight of Biogen's global legal and compliance functions. "Michael brings to Biogen a rare combination of deep legal and industry expertise as well as broad operational leadership that will further contribute to Biogen's next chapter of renewed growth," said Christopher A. Viehbacher, President and Chief Executive Officer at Biogen. "He has dedicated his career to leadership across the biopharmaceutical industry, which includes successful navigation of the complex legal and business challenges that are involved in advancing new discoveries through the development and commercial landscape. Michael's broad experience offers clear value to Biogen as we execute on our strategy and build the future of the company." Parini joins Biogen with more than 20 years of senior legal and strategic leadership experience across the biopharmaceutical and biotechnology industry. Most recently, he served as Chief Executive Officer of Spur Therapeutics, where he led a company transformation, redefining the scientific strategy and advancing a rare disease program from the pre-clinical stage into Phase 3 development. Prior to Spur Therapeutics, Parini held a series of leadership roles at Vertex Pharmaceuticals, rising to Chief Administrative, Legal and Business Development Officer, where he served on the Executive Committee and oversaw multiple functions spanning Legal, Compliance, Business Development, Human Resources, Information Technology, Quality and Corporate Communications. He helped lead the acquisitions of Exonics Therapeutics and Semma Therapeutics, as well as the negotiation of market access agreements for cystic fibrosis medicines across the United Kingdom, France, Italy, Australia, and Spain. Before Vertex, he held multiple senior roles in the legal function at Pfizer, including Chief Litigation Counsel. Parini holds a J.D. from Georgetown University Law and a B.A. in American Government and Politics from Georgetown University. About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube. Biogen Safe Harbor This news release contains forward-looking statements relating to, among others, the appointment of our new Chief Legal Officer; our strategy, plans and growth opportunities; the potential of, and expectations for, our commercial business and pipeline programs; potential regulatory discussions, submissions, filings, and approvals; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "estimate," "expect," "forecast," "goal," "guidance," "hope," "intend," "may," "objective," "outlook," "plan," "possible," "potential," "predict," "project," "prospect," "should," "target," "will," "would" or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise. Digital Media Disclosure From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors. | MEDIA CONTACT: | INVESTOR CONTACT: | | Madeleine Shin | Tim Power | | + 1 781 464 3260 | +1 781 464 2442 | | [email protected] | [email protected] |